Daniel K Nomah1,2,3, Juliana Reyes-Urueña1,3,4, Yesika Díaz1,3, Sergio Moreno1,3, Jordi Aceiton1,3, Andreu Bruguera1,2,3, Rosa M Vivanco-Hidalgo5, Jordi Casabona1,2,3,4, Pere Domingo6, Jordi Navarro7, Arkaitz Imaz8, Elisabet Deig9, Gemma Navarro10, Josep M Llibre11, Jose M Miro12. 1. Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain. 2. Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain. 3. Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain. 4. CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain. 5. Agència de Qualitat i Avaluació Sanitàries de Catalunya, Barcelona, Spain. 6. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 7. Vall d'Hebron Research Institute (VHIR), Hospital de Vall d'Hebron, Barcelona, Spain. 8. Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain. 9. Hospital General de Granollers, Granollers, Spain. 10. Unitat de VIH/SIDA, Corporació Sanitària i Universitària Parc Taulí-Universitat Autònoma de Barcelona, Sabadell, Spain. 11. Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 12. Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting. OBJECTIVES: We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH). METHODS: We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain. We used adjusted Cox regression models to assess the association between tenofovir and SARS-CoV-2 outcomes. RESULTS: After propensity score-matching, SARS-CoV-2 diagnosis rates were similar in TAF/FTC versus ABC/3TC recipients (11.6% versus 12.5%, P = 0.256); lower among TDF/FTC versus ABC/3TC recipients (9.6% versus 12.8%, P = 0.021); and lower among TDF/FTC versus TAF/FTC recipients (9.6% versus 12.1%, P = 0.012). In well-adjusted logistic regression models, TAF/FTC was no longer associated with reduced SARS-CoV-2 diagnosis [adjusted odds ratio (aOR) 0.90; 95% confidence interval (CI), 0.78-1.04] or hospitalization (aOR 0.93; 95% CI, 0.60-1.43). When compared with ABC/3TC, TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or hospitalization (aOR 0.51; 95% CI, 0.15-1.70). TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or associated hospitalization (aOR 0.33; 95% CI, 0.10-1.07) compared with TAF/FTC. CONCLUSIONS: TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management.
BACKGROUND: Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting. OBJECTIVES: We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH). METHODS: We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain. We used adjusted Cox regression models to assess the association between tenofovir and SARS-CoV-2 outcomes. RESULTS: After propensity score-matching, SARS-CoV-2 diagnosis rates were similar in TAF/FTC versus ABC/3TC recipients (11.6% versus 12.5%, P = 0.256); lower among TDF/FTC versus ABC/3TC recipients (9.6% versus 12.8%, P = 0.021); and lower among TDF/FTC versus TAF/FTC recipients (9.6% versus 12.1%, P = 0.012). In well-adjusted logistic regression models, TAF/FTC was no longer associated with reduced SARS-CoV-2 diagnosis [adjusted odds ratio (aOR) 0.90; 95% confidence interval (CI), 0.78-1.04] or hospitalization (aOR 0.93; 95% CI, 0.60-1.43). When compared with ABC/3TC, TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or hospitalization (aOR 0.51; 95% CI, 0.15-1.70). TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or associated hospitalization (aOR 0.33; 95% CI, 0.10-1.07) compared with TAF/FTC. CONCLUSIONS: TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management.
Authors: Julia Del Amo; Rosa Polo; Santiago Moreno; Asunción Díaz; Esteban Martínez; José Ramón Arribas; Inma Jarrín; Miguel A Hernán Journal: Ann Intern Med Date: 2021-04 Impact factor: 25.391
Authors: Mackenzie L Cottrell; Katy L Garrett; Heather M A Prince; Craig Sykes; Amanda Schauer; Cindi W Emerson; Anne Peery; James F Rooney; Scott McCallister; Cynthia Gay; Angela D M Kashuba Journal: J Antimicrob Chemother Date: 2017-06-01 Impact factor: 5.790
Authors: Jesper Melchjorsen; Michael W Risør; Ole S Søgaard; Kieran L O'Loughlin; Sue Chow; Søren R Paludan; Svend Ellermann-Eriksen; David W Hedley; Hans Minderman; Lars Østergaard; Martin Tolstrup Journal: J Acquir Immune Defic Syndr Date: 2011-08-01 Impact factor: 3.731
Authors: S Scott Sutton; Joseph Magagnoli; James W Hardin; Ling-I Hsu; Anne Beaubrun; Sunil Majethia; Tammy H Cummings Journal: Curr Med Res Opin Date: 2020-09-11 Impact factor: 2.580
Authors: Sanjiv M Baxi; Rebecca Scherzer; Ruth M Greenblatt; Howard Minkoff; Anjali Sharma; Mardge Cohen; Mary A Young; Alison G Abraham; Michael G Shlipak Journal: AIDS Date: 2016-02-20 Impact factor: 4.177
Authors: Tri-Long Nguyen; Gary S Collins; Jessica Spence; Jean-Pierre Daurès; P J Devereaux; Paul Landais; Yannick Le Manach Journal: BMC Med Res Methodol Date: 2017-04-28 Impact factor: 4.615